Shaowei Han

Cooperation & BD Director @ Youcare Pharmaceutical Group Co., Ltd

About

Work Experience：1、Strategic pharmaceutical leader with 5+ years driving R&D strategy, global BD, and cross-functional innovation. 2、Focused on small nucleic acid drugs, mRNA therapy, and CTG . Spearheaded a total of 26 innovative drug programs in the pipeline. Among them, 3 Class 1 traditional Chinese medicines have submitted NDA and are under review, 1 in Phase II/III, 4 in Phase II, 1 in Phase I/II, 4 in Phase I, and 13 at various pre‑clinical stages. The portfolio has secured 10 US IND approvals and 1 Australian IND approval.3、As Head of BD, led the license-in of internationally original broad-spectrum anti-coronavirus drug YKYY017 (Phase III) and managed 200+ CDAs and 5 TS milestones. 4、Built scalable proprietary medical device platforms, and successfully launched a registered mesh nebulizer to underpin the company’s peptide inhalation delivery system. Leveraging this platform, three first-in-class (FIC) drug candidates are currently under development, among which two have advanced into clinical stages.5、Expertise in regulatory strategy, capital markets, and translating science into global pipelines. Committed to bridging innovation with patient impact.6、Committed to bridging innovation with patient impact.Specialties:1、Deep expertise in China’s pharmaceutical landscape and regulatory policies.2、Strong analytical and strategic acumen to drive informed decision-making.3、Robust opportunity assessment, business case development, and project management skills to deliver tangible outcomes.4、Effective cross-functional leadership through active listening and clear communication.5、Proven ability to rapidly acquire new knowledge with strategic problem-solving expertise.

Country

City

China

Industry

Cosmetics

Skill

Interdisciplinary Research Integration, Data-Driven Experimental Design & Validation, Translational Research Pipeline Development, Innovative Target Identification & Mechanistic Elucidation, Strategic Full-Cycle Research Project Management, Strategic R&D Portfolio Optimization, Innovative Drug Pipeline Construction, Global Licensing & Partnership Strategy, Cross-Border Deal Negotiation Excellence, Regulatory-Commercial BD Synergy

Experience

Cooperation & BD Director

Youcare Pharmaceutical Group Co., Ltd

2021-7 - Present · 5 yrs 3 mos

Beijing, China

1. Maintain a sustained focus on cutting-edge advancements in small nucleic acid drugs, mRNA vaccines, viral membrane fusion inhibitor polypeptides, and cell & gene therapies, demonstrating profound industry insights. 2. As R&D Strategy Lead, orchestrated over 600 in-depth investigations across innovative drugs, generics, emerging technologies, and novel therapies. Spearheaded the initiation of 15 Class 1 innovative drug，establishing a robust R&D pipeline. Secured IND approvals for 2 projects in China, 4 in the US, and 1 in Australia; some projects have advanced to Phase III clinical trials. 3. In the role of BD Department Head, executed global License-in/out strategies for innovative drugs and core technology platforms. Engaged with 300+ projects, finalized 150+ CDAs, and progressed 30+ to the TS negotiation stage. Successfully licensed in YKYY017, an original broad - spectrum anti - coronavirus drug, now in Phase III trials. 4. Oversaw CMC research for polypeptide drugs and managed the nebulization inhalation platform. 5. Pioneered the medical device division, constructing a comprehensive R&D and registration platform, and successfully commercialized the first mesh nebulizer. 6. Spearheaded pharmaceutical policy analysis, government relations, grant applications, and select securities matters, bolstering strategic growth with policy expertise and capital support.

Researcher Assistant

Chinese Academy of Medical Sciences

2015-9 - 2018-8 · 3 yrs

BEI JING, China

Responsible for the development of Chinese medicine candidate drugs for Alzheimer’s disease prevention and treatment in the research team. 1. Led the completion of drugability studies for anti-dementia Chinese medicine candidates, including partial involvement in production process optimization, chemical composition analysis, quality standard establishment, and primary pharmacodynamic evaluation; established a comprehensive quality control system to enable scale-up production. 2.Contributed to multiple anti-dementia pharmacodynamic and toxicological studies. 3. Advanced the project to the IND enabling stage. 4. Published 5 SCI papers and applied for 2 patents.